ArticleClinical and vaccine immunology : CVI2008
Candidate antigens for Q fever serodiagnosis revealed by immunoscreening of a Coxiella burnetii protein microarray.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026Review
- B-cell peptide epitopes as diagnostic targets for Q fever in sheep.Frontiers in microbiology · 2026Article
- Evaluation of Three Recombinant Antigens for the Detection of Anti-Coxiella Antibodies in Cattle.Antibodies (Basel, Switzerland) · 2025Article
- Efficiency of recombinant Ybgf in a double antigen-ELISA for the detection of Coxiella antibodies in ruminants.Veterinary and animal science · 2024Article
- Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria.Frontiers in cellular and infection microbiology · 2024Review
- Unveiling promising immunogenic targets in Coxiella burnetii through in silico analysis: paving the way for novel vaccine strategies.BMC infectious diseases · 2023Article
- Detection ofJournal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2023Article
- Engineering Protein Nanoparticles Functionalized with an ImmunodominantBioconjugate chemistry · 2023Article
- Comparative Transcriptomics and Genomics from Continuous Axenic Media Growth IdentifiesbioRxiv : the preprint server for biology · 2023Article
- Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses toFrontiers in immunology · 2023Article
- Multivalent vaccines demonstrate immunogenicity and protect againstFrontiers in immunology · 2023Article
- Characterization of recombinant Ybgf protein for the detection ofJournal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022Article
- Development of High-Throughput Multiplex Serology to Detect Serum Antibodies againstMicroorganisms · 2021Article
- Identification of Immunogenic Linear B-Cell Epitopes inPathogens (Basel, Switzerland) · 2021Article
- Q Fever Vaccine Development: Current Strategies and Future Considerations.Pathogens (Basel, Switzerland) · 2021Review
- Proteome-wide analysis of Coxiella burnetii for conserved T-cell epitopes with presentation across multiple host species.BMC bioinformatics · 2021Article
- APRANK: Computational Prioritization of Antigenic Proteins and Peptides From Complete Pathogen Proteomes.Frontiers in immunology · 2021Article
- Validation of a Novel Commercial ELISA Test for the Detection of Antibodies againstPathogens (Basel, Switzerland) · 2020Article
- Analysis of recombinant proteins for Q fever diagnostics.Scientific reports · 2020Article
- Evaluation of the Diagnostic Potential of RecombinantMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Q fever is a widespread zoonosis caused by Coxiella burnetii. Diagnosis of Q fever is usually based on serological testing of patient serum. The diagnostic antigen of test kits is formalin-fixed phase I and phase II organisms of the Nine Mile reference strain. Deficiencies of this antigen include (i) potential for cross-reactivity with other pathogens; (ii) an inability to distinguish between C. burnetii strains; and (iii) a need to propagate and purify C. burnetii, a difficult and potentially hazardous process. Consequently, there is a need for sensitive and specific serodiagnostic tests utilizing defined antigens, such as recombinant C. burnetii protein(s). Here we describe the use of a C. burnetii protein microarray to comprehensively identify immunodominant antigens recognized by antibody in the context of human C. burnetii infection or vaccination. Transcriptionally active PCR products corresponding to 1,988 C. burnetii open reading frames (ORFs) were generated. Full-length proteins were successfully synthesized from 75% of the ORFs by using an Escherichia coli-based in vitro transcription and translation system (IVTT). Nitrocellulose microarrays were spotted with crude IVTT lysates and probed with sera from acute Q fever patients and individuals vaccinated with Q-Vax. Immune sera strongly reacted with approximately 50 C. burnetii proteins, including previously identified immunogens, an ankyrin repeat-domain containing protein, and multiple hypothetical proteins. Recombinant protein corresponding to selected array-reactive antigens was generated, and the immunoreactivity was confirmed by enzyme-linked immunosorbent assay. This sensitive and high-throughput method for identifying immunoreactive C. burnetii proteins will aid in the development of Q fever serodiagnostic tests based on recombinant antigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.